Vichem Chemie Research Ltd.
Vichem is a privately funded Biotechnology Company with 25 people and 7 PhD students. Vichem was founded in 1999 and is highly specialized in developing kinase inhibitors. The CEO of the company is Prof. Dr. György Kéri who has more than 20 years experience in kinase inhibitory chemistry in close collaboration with Prof. Axel Ullrich (Director of Max Planck Institute for Biochemistry and previous chief scientist of Genentech).
Vichem has long expertise in drug discovery for signal transduction therapy and developed a unique knowledge-base in successful collaborations with partners like the Max Planck Institute for Biochemistry, Martinsried, Germany; Sugen Inc., San Francisco, USA and Axxima Pharmaceuticals AG Munich, Germany. Our current research partners include GPC-Biotech AG, Martinsried, Germany; Institute Pasteur, Paris, France; Katholieke Universiteit, Leuven, Belgium; Medizinische Hochschule, Hannover Germany and Karolinska Institut, Stockholm, Sweden.
Vichem provides Medicinal Chemistry capabilities based on our unique, in-house developed Nested Chemical Library™ (NCL) technology. The NCL was designed on the platform of our up-to-date knowledge base what we have built up from our experience and literature data accumulated in the recent 20 years of kinase inhibitory chemistry. Our library is organized around 108 core structures, providing a very diverse kinase inhibitory library available for drug research. It contains more than 12000 potential kinase inhibitory compounds including 300 published clinically relevant leads and a big series of proprietary compounds. We have worked out a cyclic iteration process for hit and lead finding and optimization in the kinase inhibitory field. Our technology can provide patentable preclinical lead candidates against validated target molecules in the kinase inhibitory field after about five research cycles. The most important technologies of Vichem include:
- Nested Chemical Library of Kinase Inhibitors
- Chemical Validation Library and Hit finding Library with hits against 73 kinases
- Allosteric Kinase inhibitory library
- Structure biology based 3D pharmacophore model
- Ligand based Pharmacophore model
- Multiple site inhibitors based on Crossover Pharmacophore technology
- KinaTor™ technology (affinity chromatography) for selectivity profiling and with "broad band" kinase inhibitors for cross over target selection
- Lead compounds with low nanomolar IC50s for more than 20 kinase targets
- Lead optimisation and ADMET optimization
